Product
Trimodulin
Aliases
BT588
3 clinical trials
6 indications
Indication
Community-acquired PneumoniaIndication
Respiratory InfectionIndication
PneumoniaIndication
Acute Respiratory Distress SyndromeIndication
COVID-19Indication
Fungal PneumoniaClinical trial
A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase III Trial to Assess the Efficacy and Safety of Trimodulin (BT588) in Adult Hospitalized Subjects With Severe Community-acquired Pneumonia (sCAP)Status: Recruiting, Estimated PCD: 2025-02-28
Clinical trial
A Phase I, Open Label, First In Humans (FIH), Single Dose Level Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)Status: Active (not recruiting), Estimated PCD: 2026-03-01
Clinical trial
A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase II Trial Investigating the Efficacy and Safety of Trimodulin (BT588) as add-on Therapy to Standard of Care in Adult Subjects With Severe COVID-19Status: Completed, Estimated PCD: 2021-06-29